Submitted by Anonymous (not verified) on 13 November 2023 - 16:09
Human medicines European public assessment report (EPAR): Bimzelx, bimekizumab, Psoriasis, Date of authorisation: 20/08/2021, Revision: 5, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Bimzelx, bimekizumab, Psoriasis, Date of authorisation: 20/08/2021, Revision: 5, Status: Authorised